Arcturus Therapeutics Holdings (ARCT) Capital Expenditures (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has 8 years of Capital Expenditures data on file, last reported at -$88000.0 in Q4 2025.

• Quarterly Capital Expenditures changed N/A year-over-year to -$88000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $93000.0 (down 82.94% YoY) and the FY2025 annual result came in at $230000.0, down 64.51% from the prior year.
• Capital Expenditures slipped to -$88000.0 in Q4 2025, from $181000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.2 million in Q3 2022 to a low of -$3.3 million in Q4 2022.
• A 5-year average of $244722.2 and a median of $159000.0 in 2025 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 1688.98% in 2022, down 47700.0% in 2022.
• Tracing ARCT's Capital Expenditures over 5 years: stood at -$7000.0 in 2021, then sank by 47700.0% to -$3.3 million in 2022, then surged by 126.15% to $875000.0 in 2023, then plunged by 90.86% to $80000.0 in 2024, then tumbled by 210.0% to -$88000.0 in 2025.
• The last three Capital Expenditures figures came in at -$88000.0 (Q4 2025), $181000.0 (Q3 2025), and $137000.0 (Q1 2025), per Business Quant data.